Expression of fibronectin binding protein A (FnBPA) from Staphylococcus aureus at the cell surface of Lactococcus lactis improves its immunomodulatory properties when used as protein delivery vector. Issue 10 (4th March 2016)

• Record Type: Journal Article
• Authors: Almeida, Juliana F.; Breyner, Natalia M.; Mahi, Miloud; Ahmed, Bensoltane; Benbouziane, Bouasria; Boas, Priscilla C.B. Vilas; Miyoshi, Anderson; Azevedo, Vasco; Langella, Philippe; Bermúdez-Humarán, Luis G.; Chatel, Jean-Marc
• Is Part Of: Vaccine. Volume 34:Issue 10(2016)
• Page Start: 1312
• Page End: 1318
• Publication Date: 2016-03-04
• Subjects: Lactic acid bacteria -- Protein vaccination -- Fibronectin binding protein A (FnBPA) -- Human papillomavirus (HPV) -- HPV-16-E7 antigen; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2016.01.022
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: A recombinant strain of Lactococcus lactis displaying a cell-surface anchored fibronectin binding protein A (FnBPA) from Staphylococcus aureus (LL-FnBPA) had been shown to be more efficient in delivering plasmid than its wild-type counterpart both in vitro and in vivo, and have the ability to orientate the immune response toward a Th2 profile in a context of a DNA vaccination. The aim of this work was to test whether this LL-FnBPA strain could shape the immune response after mucosal administration in mice. For this, we used a mouse model of human papilloma virus (HPV)-induced cancer and a L. lactis strain displaying at its cell surface both HPV-16-E7 antigen (LL-E7) and FnBPA (LL-E7 + FnBPA). Our results revealed a more efficient systemic Th1 immune response with recombinant LL-E7 + FnBPA. Furthermore, mice vaccinated with LL-E7 + FnBPA were better protected when challenged with HPV-16-induced tumors. Altogether, the results suggest that FnBPA displays adjuvant properties when used in the context of mucosal delivery using L. lactis as a live vector.